Fibrinogen E in a therapeutic composition that inhibits angiogenesis

The anti-angiogenic effects of polypeptides derived from fibrinogen E comprising amino acids 1 to 78 of the alpha -chain and amino acids 43 to 122 of the beta -chain, and amino acids 1 to 62 of the gamma -chain are described. A number of conditions would benefit from an inhibition of angiogenesis. For example, ophthalmological conditions such as, neovascular glaucoma diabetic retinopathy age-related macular degeneration, pterygium retinopathy of prematurity choroidal and other intraocular disorders. Also, atherosclerosis haemangioma haemangioendothelioma warts Kaposi's sarcoma scar keloids allergic oedema dysfunctional uterine bleeding follicular cysts ovarian hyperstimulation endometriosis peritoneal sclerosis, adhesion formation obesity osteomyelitis pannus growth osteophyte formation inflammatory and infectious processes (egg hepatitis, pneumonia, glomerulonephritis), asthma, nasal polyps, transplantation, liver regeneration thyroiditis, thyroid enlargement and lymphoproliferative disorders.